



# The ACME Laboratories Ltd.

MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001: 2015 CERTIFIED COMPANY

O/c

Ref. No. ACME /CA/CS/0043/2019

10 April 2019

## The Chairman

Bangladesh Securities and Exchange Commission  
Securities Commission Bhaban  
E-C/6, Agargaon,  
Sher-e-Bangla Nagar Administrative Area,  
Dhaka-1207.

Subject: **Audited Status Report on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd.**

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report (as per revised format) on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 100<sup>th</sup> Meeting held on 08 April 2019 for your kind perusal and record please.

Thanking you and assuring of our best attention for all the time to come.

**Mizanur Rahman Sinha**  
Managing Director

Enclosure: As stated above



Copy to: 01. The Managing Director, Dhaka Stock Exchange Limited  
02. The Managing Director, Chittagong Stock Exchange Limited  
03. The Chief Executive Officer, ICB Capital Management Limited

### Corporate Office:

Court de la ACME  
1/4 Kallayanpur, Mirpur Road  
Dhaka-1207, Bangladesh.  
Phone : +88-02-9004194-6  
Fax : +88-02-9016872  
E-mail : headoffice@acmeglobal.com

[www.acmeglobal.com](http://www.acmeglobal.com)

### Plant:

Dhamrai, Dhaka, Bangladesh.  
Phone : +88-02-7730881-2  
+88-02-7730816-7, 7730142  
Fax : +88-02-7730141  
E-mail : plant@acmeglobal.com

# Auditors' Report



Name of Client

**The ACME Laboratories Ltd.**  
**Utilization of IPO Proceeds**  
for the month ended 31 March 2019

**পিনাকী এণ্ড কোম্পানী**  
**Pinaki & Company**

REGD. OFF : AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh  
Tel # 966-0944, 966-5095, Cell: 01317-201224, 01711-106302  
E-mail : pinaki\_co@yahoo.com, website: www.pinaki.com.bd



**AUDITORS' REPORT**  
*on*  
**Utilization of IPO Proceeds**

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of **The ACME Laboratories Ltd.** for the month ended 31 March 2019.

**Management's Responsibility for the IPO proceeds Utilization**

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

**Auditor's Responsibility**

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Opinion**

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 gives a true and fair view of the statement for the month ended 31 March 2019 and comply with the resolution of 42<sup>nd</sup> AGM of the company.

**As per TOR, We draw attention to the following matter:**

1. The Company has utilized cumulative amounting to Tk. 1,660,591,186 up to 31 January 2019 in respect of Steroid & Hormone Project. During the month of March 2019, no amount has been spent regarding the project through IPO fund.



2. The Company has utilized cumulative amount of Tk. 400,000,000 up to 31 January 2019 in respect of Penicillin Project. During the month of March 2019, no amount has been spent regarding the project through IPO fund.
3. The Company has also utilized cumulative amounting to Tk. 151,287,024 up to 31 March 2019 in respect of API Project. During the month of March 2019, no amount has been utilized out of IPO fund in respect of Active Pharmaceuticals Ingredients (API) Project.

**We also state that:**

- a) IPO proceeds have been utilized for the purposes as specified in the resolution of 42<sup>nd</sup> AGM of the company;
- b) IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- c) Utilization of IPO proceeds regarding Steroid and Hormone project as well as Penicillin Project had been completed during the month of January 2019. On the other hand API project is being under completion within the time frame as specified in the resolution of 42<sup>nd</sup> AGM of the company.
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the resolution of 42<sup>nd</sup> AGM of the company;
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Date: 08 April 2019  
Dhaka.

*Pinaki & Co*  
**Pinaki & Company**  
Chartered Accountants

Report on Utilization of IPO Proceeds  
For the Month of March 2019

Name of the Company: The ACME Laboratories Ltd.  
Amount (BDT) of capital raised through IPO: BDT 4,095,015,601.38 net of foreign currency conversion loss)  
Date of Close of Subscription: 21 April 2016  
Proceeds Receiving Date: 11 April 2016 to 21 April 2016  
Last Date of Full Utilization of IPO Fund as per 40th AGM/42nd AGM: As stated in time line columns


Sl.	Purpose mentioned in the 40th AGM/42nd AGM	Time Line		Cost Breakdown	Amount as per 40th AGM	Amount as per 42nd AGM	Opening	During the Month	Status of Utilization		Un utilized %	Remarks	
		As per 40th AGM	As per 42nd AGM						Total Utilized Amount	Utilized %			
1	Steroid and Hormone Project	Within 2 years of receiving IPO fund, i.e. 2018	Within June 2019	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Consultancy fee Contingencies Sub Total	335,800,000 598,600,000 339,600,000 39,500,000 5,000,000 26,300,000 13,200,000 1,358,000,000	334,934,878 933,900,000 353,700,000 21,986,000 5,000,000 1,200,000 9,870,308 1,660,591,186	334,934,878 933,900,000 353,700,000 21,986,000 5,000,000 1,200,000 9,870,308 1,660,591,186	-	334,934,878	100.00%	0.00%		
2	Penicillin Project	Within the month of March 2018	Within June 2019	Machinery & Equipment Utility Warehouse Vehicle Consultancy fee Contingencies Sub Total	132,299,520 117,154,000 20,582,700 3,000,000 5,963,780 5,000,000 400,000,000	142,922,303 79,768,602 146,345,797 2,901,503 1,420,250 5,000,000 400,000,000	142,922,303 79,768,602 146,345,797 2,901,503 1,420,250 5,000,000 400,000,000	-	142,922,303	100.00%	0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s Pinaki and Company, Chartered Accountants	
3	Active Pharmaceuticals Ingredients (API)	Within 2-3 years after getting permission from the Ministry of Industries	Within June 2022	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Consultancy fee Contingencies Initial Working Capital Sub Total	347,860,000 493,000,000 409,400,000 38,500,000 3,000,000 23,635,200 12,917,600 26,915,492 1,355,228,292	355,637,304 250,495,241 - - - - - - 606,132,545	151,287,024 - - - - - - - 151,287,024	-	151,287,024	42.54%	57.46%		
4	Repayment of Bank Borrowing at 40th AGM	N/A	N/A		1,360,000,000	1,360,000,000	1,360,000,000	-	-	1,360,000,000	100.00%	0.00%	
5	IPO Expenses	N/A	N/A		68,291,870	68,291,870	68,291,870	-	-	68,291,870	100.00%	0.00%	
<b>Total</b>					<b>4,541,520,162</b>	<b>4,095,015,601</b>	<b>3,640,170,080</b>	<b>-</b>	<b>-</b>	<b>3,640,170,080</b>	<b>88.89%</b>	<b>11.11%</b>	

Percentage (Interest on FDR to be matured on 27 June 2019 & 06 April 2019)  
Interest on IPO Proceeds in BDT (from FDR & SND)  
Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

  
(Fozlin Haque, FCA)  
Independent Director & Chairman of the Audit Committee

  
(Mizanur Rahman Sinha)  
Managing Director

  
(Nagma Afsar Sinha)  
Chairman

Pinaki & Company  
Chartered Accountants